• Product NameRostafuroxin(PST 2238)
• Brief DescriptionInhibitors
• Purification99.50%
• Biological ActivityA novel antihypertensive agent, rostafuroxin (PST2238), has been selected and developed for its ability to correct the renal Na(+)-K(+) pump abnormalities sustained by the mutant adducin and EO-dependent mechanisms.
• Target NameATPase inhibitor
• CAS No. 156722-18-8
• Calculated MW 374.51
• Formulation C23H34O4
• Storage 3 years -20˚C powder;2 years -80˚C in solvent;

• Research Area:Cardiovascular System
  SMILES:C[C@]12CC[C@@H](C[C@H]1CC[C@@H]3[C@@H]2CC[C@]4([C@@]3(CC[C@@]4(C5=COC=C5)O)O)C)O
  Pathways:Membrane transporter/Ion channel
  Receptor:Na+/K+-ATPase
  Boling pt:
  Melting pt:
  Solubility:DMSO: 10 mM
  Appearance:White Powder
  Remark:For obtaining a higher solubility , please warm the tube at 37 ˚C and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20 ˚C for several month.

1. Wenceslau CF, Rossoni LV. J Hypertens. 2014 Mar; 32(3): 542-54.

• Flow Cytometry (FCM) General Protocol
• Immunofluorescence(IC)
• Immunohistochemistry(Polymer)
• Western Blotting